Idioma:

Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing

Schiffman, Mark

Cancer, 2007-06, Vol.111 (3), p.145-153 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por

Enviar para

Título:
Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing
Autor: Schiffman, Mark
Assuntos: Biological and medical sciences ; cervical cancer ; Cytodiagnosis - economics ; Cytodiagnosis - methods ; Cytodiagnosis - trends ; cytology ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; human papillomavirus ; Human papillomavirus 16 - immunology ; Human papillomavirus 18 - immunology ; Humans ; Mass Screening - economics ; Mass Screening - methods ; Mass Screening - trends ; Medical sciences ; Papillomavirus Infections - diagnosis ; Papillomavirus Infections - immunology ; Papillomavirus Infections - prevention & control ; Papillomavirus Vaccines - immunology ; Papillomavirus Vaccines - therapeutic use ; testing ; Tumors ; Uterine Cervical Neoplasms - diagnosis ; Uterine Cervical Neoplasms - prevention & control ; Uterine Cervical Neoplasms - virology ; Vaccination - economics ; Vaccination - methods ; Vaccination - trends
É parte de: Cancer, 2007-06, Vol.111 (3), p.145-153
Notas: Fax: (301) 402‐0916.
These views are personal and do not reflect the official opinions of the NCI.
The National Cancer Institute (NCI) is cooperating with Glaxo Smith Kline in a randomized trial of prophylactic human papillomavirus (HPV) vaccination in Costa Rica. The company is providing the vaccines and funding for the regulatory aspects of the trial; however, data management, data analysis, and publications are entirely controlled by the NCI. The NCI collaborates with a large number of companies working on cervical cancer screening, including cytology, HPV testing, and biomarker development. All collaboration with industry colleagues is overseen by the NCI Ethics Office and is unpaid; the author has no relevant financial holdings or personal conflicts of interest.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: There is justifiable excitement about the recent introduction of prophylactic vaccines against human papillomavirus (HPV) types 16 (HPV‐16) and HPV‐18. Preventing these infections theoretically could avert approximately 70% of cervical cancer cases worldwide. In the U.S., numerous influential advocates are calling for universal vaccination of adolescent females. Given the promise of the vaccines, perhaps it is inevitable that vaccine introduction is proceeding before full consideration of how universal vaccination would affect existing, successful cervical cancer prevention programs. Determining the impact and cost effectiveness of the vaccines unavoidably will require time. Nevertheless, it is worth describing in broad terms for the readers of Cancer Cytopathology how successful, broad HPV vaccination of adolescent girls may affect cytology and HPV testing. Cancer (Cancer Cytopathology) 2007. © 2007 American Cancer Society. By removing the most evident and threatening cytologic, colposcopic, and human papillomavirus (HPV) testing results from cervical cancer prevention programs, successful HPV type 16 (HPV‐16) and HPV‐18 prophylactic vaccination will leave behind more equivocal and less predictive abnormalities. This is good news for women; however, if we vaccinate widely, we will need to adjust the rest of the cervical cancer prevention program.
Editor: Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing

Schiffman, Mark

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Buscando em bases de dados remotas. Favor aguardar.